Abstract
Multiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Adolescent
-
Age of Onset
-
Child
-
Child, Preschool
-
Cognition Disorders / etiology
-
Demyelinating Autoimmune Diseases, CNS / diagnosis
-
Diagnosis, Differential
-
Early Diagnosis
-
Female
-
Fingolimod Hydrochloride / therapeutic use
-
Humans
-
Immunologic Factors / therapeutic use
-
Infant
-
Magnetic Resonance Imaging
-
Male
-
Multiple Sclerosis* / diagnosis
-
Multiple Sclerosis* / drug therapy
-
Multiple Sclerosis* / epidemiology
-
Natalizumab / therapeutic use
-
Sphingosine 1 Phosphate Receptor Modulators / therapeutic use
-
Symptom Assessment
Substances
-
Immunologic Factors
-
Natalizumab
-
Sphingosine 1 Phosphate Receptor Modulators
-
Fingolimod Hydrochloride